Ikena Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Research and development revenue under collaboration agreement | $9,160 | $15,618 |
| Operating expenses: | ||
| Research and development | 59,652 | 64,321 |
| General and administrative | 24,925 | 22,201 |
| Total operating expenses | 84,577 | 86,522 |
| Loss from operations | (75,417) | (70,904) |
| Other income (expense): | ||
| Investment income | 7,111 | 2,149 |
| Other expense | (22) | (10) |
| Total other income, net | 7,089 | 2,139 |
| Loss before income taxes | (68,328) | (68,765) |
| Income tax benefit (expense) | 162 | — |
| Net loss | $(68,166) | $(68,765) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities | 715 | (763) |
| Total comprehensive loss | $(67,451) | $(69,528) |
| Net loss per share: | ||
| Net loss per share attributable to common stockholders basic and diluted | $(1.63) | $(1.90) |
| Weighted-average common shares outstanding, basic and diluted | 41,735,081 | 36,188,420 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.